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Abstract 
Proliferative activity, assessed by Ki67 immunohistochemistry (IHC), is an established prognostic 
and predictive biomarker of breast cancer (BC). However, it remains under-utilized due to lack of 
standardized robust measurement methodologies and significant intratumor heterogeneity of 
expression. A recently proposed methodology for IHC biomarker assessment in whole slide images 
(WSI), based on systematic subsampling of tissue information extracted by digital image analysis 
(DIA) into hexagonal tiling arrays, enables computation of a comprehensive set of Ki67 indicators, 
including intratumor variability. In this study the tiling methodology was applied to assess Ki67 
expression in WSI of 152 surgically removed Ki67-stained (on full-face sections) BC specimens 
and to test which, if any, Ki67 indicators can predict overall survival (OS). Visual Ki67 IHC 
estimates and conventional clinico-pathologic parameters were also included in the study. Analysis 
revealed linearly independent intrinsic factors of the Ki67 IHC variance: Proliferation (level of 
expression), Disordered texture (entropy), Tumor size and Nottingham Prognostic Index, 
Bimodality, and Correlation. All visual and DIA-generated indicators of the level of Ki67 
expression provided significant cut-off values as single predictors of OS. However, only bimodality 
indicators (Ashman’s D, in particular) were independent predictors of OS in the context of hormone 
receptor and HER2 status. From this we conclude that spatial heterogeneity of proliferative tumor 
activity, measured by DIA of Ki67 IHC expression and analyzed by the hexagonal tiling approach, 
can serve as an independent prognostic indicator of OS in BC patients that outperforms the 
prognostic power of the level of proliferative activity. 
Keywords: breast cancer, immunohistochemistry, digital pathology, automated image analysis, 
Ki-67, heterogeneity, hexagonal tiling, honeycomb 
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Introduction 
Proliferative activity of tumor tissue, commonly measured by Ki67 immunohistochemistry (IHC), 
remains in the spot light of breast cancer pathology: depending on the tumor type and the clinical 
setting, Ki67 is a well-established prognostic and a predictive marker [1].  However, its clinical 
application is hindered by the lack of standardized measurement methodologies and clearly defined 
cut-offs. After initial recommendation of a cut-off based on gene-expression definition of Luminal 
A breast cancer from a single reference laboratory [2], it became evident that cut-offs between 
“high” and “low” values for Ki67 vary between laboratories and should be adjusted to the local 
practices [3]. Petrelli et al [4] recently published a systematic review on prognostic value of 
different cut-off IHC levels of Ki67 in breast cancer, based on meta-analysis of 64,196 patients. It 
was concluded that Ki67 is an independent prognostic marker for overall survival (OS) in breast 
cancer patients; the threshold with the greatest prognostic significance remains ill-defined, although 
a cut-off >25% was associated with a greater risk of death. However, an evidence-based “optimal” 
cut-off cannot be achieved without robust measurement techniques, therefore, Ki67 potentially 
should be used as a continuous biomarker. 
Besides the need for accurate measurement of the proportion of the Ki67 labelling index (Ki67 LI), 
which is simply the proportion of Ki67-positive tumor cell profiles within a defined malignant cell 
population, the assay is further complicated by its’ intratumor heterogeneity. This involves an 
additional step of standardized choice of the tissue for evaluation. Detection and evaluation of 
hotspots of Ki67 expression in the tumor tissue can be performed by conventional microscopy, by 
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review of whole slide images (WSI), or with the assistance of digital image analysis (DIA) tools [5, 
6]. However, standardized definitions of hotspots, in terms of their size, shape, and contrast to the 
surrounding tissue, are needed and do present another challenge for both human and machine-based 
measurements [7, 8]. 
A recently proposed a methodology for comprehensive Ki67 IHC evaluation in WSI of breast 
cancer tissue [8], is based on the systematic subsampling of DIA-generated data into a hexagonal 
tiling (HexT) arrays (honeycomb). It enables computation of a comprehensive set of texture and 
distribution indicators for Ki67 intratumor variability and has the ability to reveal intrinsic factors 
behind the Ki67 IHC variance, interpreted as proliferation, entropy, bimodality, and cellularity. It 
also enables automated detection, quantitative evaluation, and augmented visualization of Ki67 
hotspots, based on the upper quintile of the HexT data, conceptualized as "Pareto hotspot". The 
methodology was tested on 297 breast cancer WSI; however, the patient follow-up data were not 
available to test clinical utility of the approach. 
This study, performed on a different patient cohort (Nottingham, UK), with the HexT methodology 
applied on another DIA tool, provides further support for the principle of HexT methodology in 
Ki67 assessment and demonstrates that intratumor heterogeneity, rather than the level of Ki67 
expression in the tumor tissue, is an independent predictor of OS in breast cancer patients. 
Materials and Methods 
Study population and tumor characteristics  
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A series of 182 patients from the Nottingham-Tenovus Primary Breast Carcinoma Series, aged 70 
years or less, presenting with primary operable (stages I, II and IIIa) invasive BC between 1986-98 
were used. This is a well-characterized consecutive series of patients who were uniformly treated 
according to locally-agreed clinical protocols [9, 10]. All tumors were ≤5 cm diameter on histology 
of surgical specimens (pT1 and pT2).  Women aged over 70 years were not included because of the 
increased confounding effect of co-morbidities/death from other causes and because the primary 
treatment protocols for elderly patients often differed from those for younger women. Adjuvant 
systemic therapies were offered according to the Nottingham Prognostic Index (NPI) [11] and 
hormone receptor (HR) status. Patients in the Moderate I group (NPI 3.41-4.4) with HR-positive 
tumors were offered hormonal therapy. Patients in the Moderate II (NPI 4.41-5.4) and Poor (NPI 
>5.41) groups received hormone therapy for HR-positive tumors and cytotoxic therapy (classical 
cyclophosphamide, methotrexate and 5-fluorouracil (CMF)) for HR-negative tumors and if the 
patient was fit enough to tolerate chemotherapy. Cases were previously stained for Ki67 [12] using 
full-face tissue sections and scored as previously described; Ki67 LI, established in the previous 
study, was utilized in the current study for comparison. ER and PR were assessed as previously 
described [9] and more than 1% staining was deemed positive. HER2 was assessed by using IHC 
and dual-color chromogenic in situ hybridization as previously described [13].  
This study was approved by the Nottingham Research Ethics Committee 2 under the title 
“Development of a molecular genetic classification of breast cancer”. 
After visual assessment of Ki67 IHC stained slides, five cases were excluded from the study due to 
the IHC staining quality issues and/or tissue artefacts. In addition, based on DIA-generated and 
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HexT-processed data, minimum sampling requirements for spatial heterogeneity testing were 
applied (see below), with 152 cases remaining in this study.  Clinico-pathological characteristics of 
the 152 cases are summarized in the Table 1.  
Image acquisition and analysis 
Digital images were recorded for the study, using a ScanScope XT Slide Scanner (Leica Aperio 
Technologies, Vista, CA, USA) under 20x objective magnification (0.5µm resolution). The DIA 
was performed on the WSI using the HALOTM Classifier Module/CytoNuclear v1.4 algorithm 
(Indica Labs, NM, USA) within manually selected region of interest (ROI) enclosing the tumor 
tissue section. The HALO Classifier was trained to detect tumor cells, while eliminating fibrous and 
inflammatory stromal compartment, and to enumerate Ki67-positive and negative tumor nuclear 
profiles in the breast cancer tissue. The tool was not trained to distinguish between invasive 
carcinoma and non-invasive ductal carcinoma in situ (DCIS); therefore, DCIS component was 
excluded by manual annotations. Quality of automated tumor and stroma segmentation and Ki67 
positivity threshold by the DIA was monitored by visual inspection; reference standard for the 
accuracy evaluation was not established in this study. 
Computation of heterogeneity parameters from hexagon tiling of the DIA-generated data 
DIA results represented by Ki67-negative and Ki67-positive tumor cell nuclei with their X and Y 
coordinates in the WSI were partitioned into HexT, from which intratumor variance indicators were 
computed. The process is here described briefly, an in-depth description is available in [8]. Briefly, 
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Hexagons of 825 pixel size corresponding to 0.75 mm circular diameter and 0.4421 mm2 area were 
used in this study. HexT was generated to fit the area of the ROI, and the individual nuclei extracted 
by DIA were assigned to an appropriate hexagon based on their coordinates. Hexagons containing 
no nuclear profiles by DIA were regarded as missing data; hexagons containing fewer than 100 
nuclear profiles were regarded as insufficiently sampled. A minimum requirement of 20 informative 
hexagons per tumor was applied in further analyses. Local Ki67% was calculated for each hexagon 
which was then ranked according to six Ki67 LI intervals: level 0 (0% - 10%), level 1 (>10% - 
20%), level 2 (>20% - 30%), level 3 (>30% - 50%), level 4 (>50% - 80%) and level 5 (>80% - 
100%). The ranks then formed the basis for the co-occurrence matrix used to compute Haralick 
texture parameters. Of the 14 classical Haralick parameters [14], 6 were computed from the 
normalized co-occurrence matrix. Bimodality indicators (Ashman's D, bimodality index) were 
calculated based on search of two hidden distributions in a mono-parametric histogram of the HexT 
data. The search was performed using the algorithm for the Gaussian Mixture Models, [15] based 
on the Expectation-Maximum [16] algorithm.  
An example of the HexT analysis results is presented in Fig. 1. Local Ki67% values for each 
hexagon are computed from the DIA data and overlaid on the original WSI with the hexagon color 
code representing the level of local Ki67%. The HexT data (represented by the local Ki67% values 
and their coordinates in the WSI) are used to compute texture and distribution indicators for 
individual tumors. As a result, average Ki67%, obtained by the DIA for each tumor, is 
supplemented by comprehensive quantitative characteristics of the intratumor variance 
(heterogeneity) of Ki67 expression (e.g., spatial entropy, bimodality, etc.). In addition, hexagons 
representing the upper quintile of the local Ki67% distribution indicate approximately 20% of the 
tumor tissue area revealing the highest biomarker expression (Pareto hotspot). 
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Hotspot detection by visual review of the WSI 
Four observers (AM, IA, JB, RM) independently reviewed all WSI at low magnification and 
annotated up to 3 freeform areas to delineate the Ki67 hotspots in the tumor tissue within the 
invasive tumor component, if present. These hotspots should be free of i) tissue folding, ii) any 
staining artefacts, iii) tissue necrosis, iv) staining edge effect. Inter-observer agreement of the visual 
hotspot detection was evaluated. Each observer provided semi-quantitative score of Ki67% in the 
tumor tissue represented by average Ki67% and hotspot Ki67%, if detected. Final Ki67% score was 
calculated by substituting the average Ki67% by hotspot Ki67%, if established. Final Ki67% scores 
of the individual observers were averaged for further analyses (Ki67 Obs Mean). 
Statistical analysis 
Statistical analysis was performed with SAS 9.4 software. Summary statistics and distribution 
analyses were performed with significance tests based on the paired sample t-test, one-way ANOVA 
with Bonferoni test for pairwise comparisons. Chi-squared and Fisher’s exact test were used to 
estimate significant associations in non-parametric statistics. Inter-observer agreement was tested 
by kappa statistics. Factor analysis was performed using the factoring method of principal 
component analysis; 5 factors were retained based on a minimum eigenvalue threshold of 1.3, and a 
general orthomax rotation of the initial factors was performed. Product-limit estimates were used to 
summarize overall survival data and the log rank test was used for comparing OS distributions. OS 
was defined as the time from the breast surgery to the patient’s survival at the end of the follow up 
period. Cox proportional hazards analysis was used to develop a multiple variable model to predict 
time to death. A combination of forward, backward, and stepwise procedures was used to arrive at 
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the final model. Continuous variables were dichotomised to predict OS using the web-based tool 
“Cutoff Finder” [17]. Statistical significance was set at p<0.05 (two-sided). 
Results 
Criteria and results of sampling the DIA-generated data into HexT 
The DIA-generated data from 152 WSI were subsampled into HexT, with the minimum requirement 
of 20 hexagons, each containing at least 100 nuclear profiles, per WSI. The summary statistics of 
the visual evaluation data, DIA, HexT, and computed indicators is presented in the Online Resource 
2. 
The tumor area analyzed per WSI ranged from 4 to 164 mm², with a median of 29 mm² (overall, 
over 13 million cells in the tumor area of 6,000 mm2 were evaluated). Paired t-test revealed 
significant underestimation bias (-7.4±16.8, p<0.0001) between the Ki67 Obs Mean score and 
Ki67% obtained from the WSI DIA; the latter “underestimated” the Ki67 LI (-11.6±30.1, p<0.0001) 
established in the previous study [12]; the ICC between the 3 variables was 0.47 (moderate). 
Remarkably, the Ki67 Obs Mean score underestimated the Ki67 LI (-19.0±25.0, p<0.0001), while 
the latter did not differ (-1.2±31.7, p=0.63) from the Ki67% 90th Percentile.  
Hotspot detection by visual review of the WSI 
While reviewing 152 WSI, each of the 4 observers identified respectively 37, 67, 32, and 27 tumors 
with at least one hotspot. The area of the hotspot annotations provided by the observers varied from 
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1.5 to 5.7 mm2 (Online Resource 2); accordingly, the relative (to the whole tumor) area of the 
hotspots varied from 3.3 to 14.6%. The agreement between the observers (taken pairwise) in 
detecting at least one hotspot was estimated by kappa coefficients ranging from 0.20 to 0.50. 
Consequently, hotspots were identified in 33, 23, 12, or 11 tumors by any one, two, three, or all four 
observers, respectively. Analysis of the actual areas and hotspot overlaps outlined by 2 or more 
observers in the 46 tumors (as above) revealed that, on average, 24.4%, 13.9%, and 4.4% of the 
hotspot areas coincided between the 2, 3, and all 4 observers, respectively.  
Detection of a hotspot by each of the four observers increased their final Ki67% score in average by 
14.0±6.1, 14.0±6.2, 13.1±10.1, and 10.2±2 percent points, respectively. The ICC between the 4 
observers in evaluation of the average Ki67% and final Ki67% was 0.78 (substantial) and 0.81 
(almost perfect), respectively. The tumors with hotspots detected by at least two observers were 
characterized by higher entropy (p<0.03), higher correlation (p<0.05), and lower energy (p<0.02) 
values but did not differ with regard to the other Haralick or bimodality indicators. 
Factor analysis of the comprehensive Ki67 indicators 
Factor analysis was performed on 152 patients with a complete set of DIA HexT data along with 
selected pathology data. The rotated factor pattern of the 5 factors, extracted with eigenvalues of 
8.8, 4.2, 2.8, 1.8, and 1.3, respectively, is presented in Fig. 1. Factor 1 was characterized by positive 
and very similar loadings of the various Ki67% indicators, accompanied by low skewness of the 
Ki67% distribution in the HexT. Factor 1 therefore was best interpreted as the “Proliferation” factor. 
Factor 2 was characterized by strong positive loadings of the Haralick indicators of “Disordered 
texture” (Contrast, Dissimilarity, Entropy) and negative loadings of Energy and Homogeneity. 
Interestingly, standard deviation and interquartile range of the Ki67 distribution contributed equally 
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to both factor 1 and factor 2. Factor 3 was characterized by positive loadings of reflective of tumor 
sample size evaluated by DIA (Total cells and Tumor area) and pathology report (Tumor size) along 
with the NPI. Factor 4 was represented by both bimodality indicators, while Factor 5 was 
characterized by the Correlation parameter and Cellularity (tumor cell density) of the tumor. The 
factor scores revealed normal distribution, a non-linear relationship between factor 1 and 2 was 
noted (not shown), consistent with that reported in the previous study [18], namely, higher scores of 
factor 2 (Disordered texture) were noted in the tumors with moderate scores of factor 1 
(proliferative activity). 
Rotated factor loadings, also with inclusion of the mean values of observers (Ki67 Obs Mean), and 
Ki67 LI, are presented in the Online Resource 2. The factor pattern remained essentially the same; 
however, lower loadings of the visual scoring data on the factor 1 values could be noted. 
Associations between the Ki67 indicators and pathology characteristics of the tumors 
Associations of the tumor Ki67 indicators and the factor scores with relevant tumor characteristics 
were explored by ANOVA. In particular, the histological grade (G) was associated with higher 
factor 1 (p<0.0001) and factor 3 (p<0.0001) scores as well the corresponding primary variables. 
Triple negative tumors revealed higher factor 1 scores compared to the HR positive tumors 
(p<0.05). Triple negative tumors and HER2 positive tumors revealed higher NPI compared to the 
HR positive tumors (p<0.05). Factor 2, 4, and 5 scores did not reveal significant associations. 
Predictors of the overall survival of the patients 
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Mean duration of follow-up after the surgery was 143.4±71.4 months (range 5 to 248 months, 
median 156). Seventy-nine patients died during the follow-up period. The G, tumor stage, axillary 
nodal stage (N), NPI category, and patient’s age group did not predict the OS by product-limit 
analysis. 
Several multivariable models were developed to account simultaneously for the comprehensive 
Ki67 indicators and other characteristics of the tumors to predict OS (Table 2). Model#1 and #2 
were derived from a dataset consisting of patient’s age, pathological parameters and the 
comprehensive Ki67 indicators, as primary variables or factor scores. Both models revealed 
independent prognostic value of worse OS for Ki67 bimodality indicators (Ashman’s D or factor 4 
scores) in the context of HR and HER2 positivity. Model#3 and #4 were obtained by adding the 
therapy modes to the dataset, where chemotherapy predicted better OS (of note, chemotherapy was 
not a significant single predictor of OS). Remarkably, none of the Ki67 indicators of the level of 
proliferative activity (Ki67 LI, Ki67 Obs Mean, Ki67 WSI. or Ki67 HexT Mean, median, 
Percentiles) could be verified as significant independent predictors of OS in this dataset. 
The Ki67 indicators and factor scores were dichotomised using the web-based tool “Cutoff 
Finder” [17] and were analyzed using Kaplan–Meier estimates and log rank tests. Many indicators 
allowed significant dichotomization of the patients into the prognostic subgroups (Fig. 3). 
Bimodality of Ki67 intratumor expression, represented by factor 4 scores (p=0.0081) and Ashman’s 
D (p=0.0017) but not bimodality index (p=0.07, not shown), provided significant cut-off values to 
predict OS. The level of proliferative activity, represented by broad range of indicators (factor 1 
scores, Ki67 HexT Mean, Median, Percentiles, Ki67 LI, Ki67 Obs Mean, Positive cell density) 
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served as significant single predictor as well. Importantly, other indicators of Ki67% distribution 
(standard deviation, interquartile range, skewness) and spatial heterogeneity (factor 5 scores, 
correlation, entropy) also provided significant cut-off values. Factor 2 (disordered texture) did not 
reach statistical significance (p=0.14), while factor 3 (tumor size and NPI) provided highly 
significant cutoff (p<0.0001, not shown).  
Discussion 
Our study reveals that spatial heterogeneity of proliferative tumor activity, measured by DIA of 
Ki67 IHC expression and analyzed by the HexT approach, can serve as an independent prognostic 
indicator of OS in breast cancer patients that outperforms the prognostic power of the level of 
proliferative activity. 
A broad set of Ki67 IHC parameters, representing the level of proliferation, pattern of distribution 
in the tissue, bimodality and texture indicators were tested in prognostic models along with 
conventional clinico-pathologic characteristics of the breast cancer patients. Remarkably, although 
all visual and machine-generated indicators of the level of Ki67 expression in this study provided 
significant cut-off values as single predictors of OS, only bimodality indicators (Ashman’s D, in 
particular) served as the independent OS predictors in the context of HR and HER2 status. Other 
indicators of Ki67 spatial heterogeneity - entropy, energy, and correlation - were also significant as 
single predictors; however, they were “out-powered” in the multivariate Cox regression model. It is 
likely that the Ashman's D bimodality is a more sensitive indicator of intratumor heterogeneity than 
the parameters computed from the covariance matrix based on Ki67% ranks (Ashman's D is 
computed from histograms, searching for two Gaussian functions, taking into account the distance 
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between the spikes and the thickness of each peak). In addition, bimodality indicators do not 
account for and are independent of spatial peculiarities of the individual tumor samples (size, shape, 
continuity of growth, etc.), which may cause “noise” in the indicators computed from the 
covariance matrix. Therefore, although our study presents an independent prognostic value of 
bimodality indicators, our findings can be indicative of the role of intratumor heterogeneity of the 
proliferative activity in general. 
Clinical utility of Ki67 IHC as prognostic and predictive factor in breast and other cancers is greatly 
obscured by the lack of standardized measurement methodologies. Our data are in line with this 
notion: we found significant bias between Ki67% measured as microscope-based Ki67 LI in the 
previous study [12], DIA, and visual evaluation of the WSI on computer monitor. Furthermore, our 
study revealed that four observers showed rather low agreement in visual detection of at least one 
hotspot (kappa ranging from 0.2 to 0.5). Moreover, the size and shape of the hotspots and their 
spatial overlap varied greatly between the cases and observers. Without proper definitions and 
standardization of the hotspot detection, the efforts to find hotspots with subsequent evaluation of 
Ki67 expression may be another source of variation for Ki67 LI measurement. It is also remarkable 
that the tumors, with at least two observers detecting at least one hotspot, revealed significantly 
higher entropy, higher correlation and lower energy; however, they were not associated with the 
bimodality indicators. Employment of DIA technologies may be useful in automated detection and 
standardization of the size and other characteristics of the hotspots. In particular, the HexT approach 
enables automated evaluation of hotspots of desired absolute or relative size; for example, the 
Pareto hotspot would always reflect Ki67% in 20% of “the “hottest tumor” area with the 90th 
percentile representing the median value in this subsampled tumor tissue [7]. 
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Our finding, that bimodality of Ki67% distribution in the tumor tissue may be a more important 
prognostic factor of OS than the level of Ki67% itself, is somewhat unexpected but may have great 
practical impact. While efforts to standardize Ki67 LI measurements and to define clinically valid 
cut-offs can lead to consensus and recommendations [4], DIA tools can be calibrated [19], it is 
challenging to ensure the analytic accuracy of the IHC test where high precision of quantification is 
required. Biological variability of the tumors and tissue processing variation may interfere with the 
DIA-based approaches. In that regard, the bimodality and other tissue heterogeneity indicators may 
prove to be more robust and less sensitive to these variations. 
Our data suggest that variability of intratumor proliferative activity may be a fundamental feature of 
tumor aggressiveness affecting final outcome of the disease, even more important than the average 
level of proliferation in tumor tissue. At least, it is an independent factor of the disease behavior. It 
is intriguing that in our study the level of proliferation (factor 1) and tumor size/NPI (factor 3) were 
associated with the histological grade (G), while the heterogeneity indicators (factor 2, 4, and 5 
scores) did not reveal significant clinico-pathologic associations, except the impact on OS. It should 
also be taken into account that the factors extracted from the comprehensive Ki67 IHC dataset are 
linearly independent by definition. Moreover, we noted non-linear relationship between the factor 1 
and 2, comparable to that reported previously in another patient cohort [18]: higher scores of the 
factor 2 (disordered texture) were noted in the tumors with moderate scores of the factor 1 
(proliferative activity). It can be interpreted that intratumor spatial heterogeneity of the proliferative 
activity is a potential feature of tumors in the mid-scale of proliferative activity and represents an 
independent factor of unfavorable disease outcome.  
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Last but not least, our current study provides additional proof of principle for the HexT approach 
[3]: while the first study was based on different DIA tool (Aperio/Leica) and different patient 
cohort, the HexT approach generated essentially the same factor pattern and clinico-pathologic 
associations of the comprehensive Ki67 indicators (the patient follow-up data was not available in 
the previous study). This demonstrates that the HexT approach, which has been successfully applied 
in many aspects in image processing and machine vision related fields [20], has its potential in the 
field of microscopy images and can serve as a tool for comprehensive IHC test. Likely, this 
approach can be applied to any IHC or other tissue-based biomarkers where intra-tissue 
heterogeneity needs to be assessed [18, 21-23]. 
In summary, intratumor heterogeneity of proliferative activity, represented by bimodality indicators, 
is an independent prognostic factor of worse OS in breast cancer patients, while the level of 
proliferative activity was significant only in univariate prognostic models. Our study supports the 
concept that assessment of IHC staining, based on the “honeycomb subsampling” of DIA data, 
enables comprehensive and efficient methodology for tissue-based biomarker testing. Furthermore, 
our findings indicate that tissue-based biomarker assessment should take into account intra-tissue 
heterogeneity aspects to reveal invisible aspects of disease, benefiting from methodologies enabled 
by digital pathology.  
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FIGURE LEGENDS 
Figure 1. Rotated factor pattern of the comprehensive Ki67 indicators and pathology data; 
n=152. 
The factor loadings of the comprehensive Ki67 indicators and pathology data (Tumor size and NPI) 
are plotted. 
Figure 2. An example of two tumors with Ki67 bimodality detected. 
The color code for the Ki67% levels in the honeycomb is as follows: dark blue (0%-10%), light 
blue (10%-20%), green (20%-30%), yellow (30%-50%). The x axis of the histograms corresponds 
to the Ki67%; the y axis represents a number of hexagons. The first tumor (on the left), was 
evaluated as Ki67 LI=47%, Ki67 Observer Mean=30%, Ki67 HexT Mean=16%, Ki67 HexT 
Median=14%; the second tumor (on the right), as Ki67 LI=25%, Ki67 Observer Mean=22%, Ki67 
HexT Mean=17%, Ki67 HexT Median=15%. Both tumors revealed high bimodality (Ashman’s D 
3.2 and 2.7) and entropy (2.9 and 3.4). Hotspots were detected by two observers in the first tumor 
while none of the observers detected a hotspot in the second tumor. 
Figure 3. Cut-off values for the Ki67 indicators as single predictors of overall survival. 
Overall survival probability plots for the Ki67 indicators are presented. The patients were stratified 
by the cut-off values obtained by the “Cutoff Finder” [17]. 
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Table 1. Patient and tumor characteristics of the study population. 
Characteristics Number (%) 
Age group  
   Age ≤ 55 years  85 (56%) 
   Age > 55 years  67 (44%) 
Histological type  
   Invasive ductal/No special type 104 (68%) 
   Other types 48 (32%) 
Subtype (n=149)  
   HR positive 101 (68%) 
   HER2 positive* 22 (15%) 
   Triple negative 26 (17%) 
Axillary nodal stage  
   1 78 (51%) 
   2 58 (38%) 
   3 16 (11%) 
Axillary lymph node status  
   Negative 78 (51%) 
   Positive 74 (49%) 
Histological grade  
   1 9 (6%) 
   2 52 (34%) 
   3 91 (60%) 
NPI**  
   Good  31 (21%) 
   Moderate 81 (53%) 
   Poor 40 (26%) 
Endocrine therapy (n=145) 81 (56%) 
Chemotherapy (n=151) 28 (19%) 
* Includes 10 HR positive cases. 
** Nottingham Prognostic Index.  
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Table 2. Summary statistics of the WSI DIA, HexT, and visual evaluation data. 
  
         Variable Mean Median Std Dev Min Max 
Upper 
quartile 
90th 
Pctl N 
Area of tumor analyzed (mm2) 39.5 29.2 33.3 4.1 164.3 49.6 82.3 152 
Total Cells 88,505 63,421 80,306 8,802 424,771 98,594 210,063 152 
Density of nuclear  profiles per mm2 of  the 
tumor area (Cellularity) 
2,258 2,192 509 1,285 4,301 2,495 2,927 152 
Density of positive nuclei per mm2 of  the 
tumor area (Positive Density) 
719 644 494 20 2,558 1,018 1,361 152 
Ki67 Observer-1 final score 21 15 19 0 80 30 50 152 
Ki67 Observer-2 final score 28 20 22 0 90 40 60 152 
Ki67 Observer-3 final score 26 13 28 0 95 43 75 152 
Ki67 Observer-4 final score 27 15 26 1 95 40 70 152 
Ki67 Observer final score (mean) 25 17 22 0 86 37 59 152 
Ki67 LI (from previous study) 44 40 32 1 97 75 87 152 
Ki67% WSI (% Positive) 32.6 31.7 20.9 1.1 86.9 46.1 60.0 152 
Ki67% HexT (% Positive Mean) 30.9 30.5 20.4 1.0 85.4 44.3 59.0 152 
Ki67% HexT (% Positive Median) 30.2 29.6 21.1 0.7 86.6 43.5 59.0 152 
Ki67% HexT (% Positive P75) 36.6 36.6 22.9 1.4 90.2 53.3 69.6 152 
Ki67% HexT (% Positive P90) 43.0 42.5 24.1 2.4 93.2 61.8 76.9 152 
Ki67% HexT (% Positive P95) 47.0 46.9 24.6 2.8 96.1 65.5 80.3 152 
Ki67% HexT (Interquartile Range) 12.2 11.6 6.4 1.2 29.8 16.4 20.3 152 
Ki67% HexT (StdDev) 9.3 9.6 4.0 0.9 17.4 12.1 14.6 152 
Ki67% HexT (Skewness) 0.6 0.5 0.9 -2.7 4.9 1.2 1.7 152 
Ki67% HexT (Kurtosis) 1.4 0.3 3.7 -1.4 34.9 1.7 4.3 152 
Entropy 2.29 2.45 0.95 0.00 4.00 2.96 3.30 152 
Dissimilarity 0.42 0.42 0.20 0.00 0.94 0.57 0.64 152 
Contrast 0.52 0.49 0.30 0.00 1.56 0.70 0.91 152 
Homogeneity 0.80 0.80 0.09 0.59 1.00 0.85 0.94 152 
Energy 0.33 0.25 0.24 0.07 1.00 0.39 0.75 152 
Correlation 0.37 0.34 0.23 -0.18 1.00 0.51 0.62 152 
Table 2
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Ashman's D 2.25 2.05 1.16 0.02 8.55 2.69 3.62 152 
Bimodality Index 1.60 1.55 0.66 0.02 4.29 1.87 2.23 152 
Number of hexagons in HexT per WSI 118 92 93 20 427 160 244 152 
Ki67 Observer-1 average score 17 12 16 0 80 25 40 152 
Ki67 Observer-2 average score 21 15 19 0 80 30 50 152 
Ki67 Observer-3 average score 23 13 26 0 95 40 60 152 
Ki67 Observer-4 average score 25 15 24 1 90 40 70 152 
Ki67 Observer-1 hotspot area (mm2) 1.49 1.10 1.40 0.17 7.27 1.69 3.05 37 
Ki67 Observer-2 hotspot area (mm2) 2.94 2.00 3.41 0.26 25.09 2.87 6.21 67 
Ki67 Observer-3 hotspot area (mm2) 6.23 5.86 3.71 0.86 18.23 8.13 9.65 32 
Ki67 Observer-4 hotspot area (mm2) 5.74 4.00 6.22 0.99 30.33 6.01 14.08 27 
Ki67 Observer-1 hotspot area proportion 0.0331 0.0248 0.0295 0.0048 0.1699 0.0398 0.0670 37 
Ki67 Observer-2 hotspot area proportion 0.0996 0.0529 0.1523 0.0071 0.9942 0.1146 0.1466 67 
Ki67 Observer-3 hotspot area proportion 0.1461 0.1291 0.0988 0.0139 0.4847 0.1906 0.2367 32 
Ki67 Observer-4 hotspot area proportion 0.1265 0.1164 0.0748 0.0156 0.2926 0.1795 0.2481 27 
 
 
 
 1 
Table 3. Cox multivariate regression models to predict overall survival of the patients. 
 Hazard ratio 95% confidence limits           P value 
Model #1 (n=147)   0.0048 
      HR positive 0.662 (0.504, 0.869) 0.0030 
      Ashman’s D 1.320 (1.035, 1.685) 0.0254 
Model #2 (n=147)   0.0008 
      HR positive 0.645 (0.489, 0.851) 0.0019 
      HER2 positive 2.178 (1.016, 4.669) 0.0455 
      Factor 4 1.592 (1.186, 2.186) 0.0020 
Model #3 (n=141)   0.0030 
      HR positive 0.501 (0.359, 0.700) 0.0001 
      HER2 positive 2.800 (1.248, 6.279) 0.0125 
      Ashman’s D 1.322 (1.030, 1.724) 0.0288 
      Chemotherapy 0.384 (0.184, 0.801) 0.0107 
Model #4 (n=141)   0.0001 
      HR positive 0.498 (0.358, 0.691) 0.0001 
      HER2 positive 2.932 (1.312, 6.550) 0.0087 
      Factor 4 1.538 (1.134, 2.087) 0.0056 
      Chemotherapy 0.381 (0.185, 0.787) 0.0090 
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